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Abstract
Background:  The catechol-O-methyltransferase (COMT) gene contains a functional
polymorphism, Val158Met which has been related to common diseases like cancer, psychiatric
illness and myocardial infarction. Whether the Val158Met polymorphism is associated with survival
has not been evaluated in the general population. The aim of this prospective study was to evaluate
the impact of codon 158 COMT gene polymorphism on survival in a population-based cohort.
Methods: The sample comprised 2979 non-diabetic individuals who participated in the Nord-
Trøndelag Health Study (HUNT) in the period 1995–97. The subjects were followed up with
respect to mortality throughout year 2004.
Results: 212 men and 183 women died during the follow up. No association between codon 158
COMT gene polymorphism and survival was found. The unadjusted relative risk of death by non-
ischemic heart diseases with Met/Met or Met/Val genotypes was 3.27 (95% confidence interval,
1.19–9.00) compared to Val/Val genotype. When we adjusted for age, gender, smoking, coffee
intake and body mass index the relative risk decreased to 2.89 (95% confidence interval, 1.04–8.00).
Conclusion: During 10 year of follow-up, the Val158Met polymorphism had no impact on survival
in a general population. Difference in mortality rates from non-ischemic heart diseases may be
incidental and should be evaluated in other studies.
Background
The catechol-O-methyltransferase (COMT) gene located
at chromosome 22q11.2 contains a functional polymor-
phism at codon 158 that has been the subject of several
molecular epidemiological studies because of the impor-
tant role of the COMT enzyme in the metabolism of cate-
cholamines and catechol estrogens. A substitution of
valine (Val) by methionine (Met) at codon 158 affects the
activity of the COMT enzyme, and individuals with the
Val/Val genotype have a three- to fourfold higher activity
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of the COMT enzyme than those with Met/Met genotype
[1].
The Val158Met polymorphism has been linked to e.g.
psychiatric disorders and pain perception [2-4], and sev-
eral epidemiological studies have also reported an associ-
ation to several potential fatal disorders. Presence of the
Val/Val genotype has been considered to be favorable
because it seems to lower the risk of developing non-
Hodgkin lymphoma and estrogen-associated cancers in
women [5-7], and because it is associated with a higher
tendency to remain free from increase in prostate-specific
antigen in men with prostate cancer [8]. Men with Val/Val
genotype may also be less likely to commit suicide [9],
and the Val allele has proved to be associated with less
aggressive behaviors or violent suicide attempts in schizo-
phrenic patients [10,11]. On the other hand, the Val/Val
genotype seems to give a higher risk of myocardial infarc-
tion among hypertensive patients [12], and it has also
been associated with high systolic blood pressure [13].
Despite the large number of studies evaluating the rela-
tionship between Val158Met polymorphism and dis-
eases, the influence of this polymorphism on survival has
not been evaluated. The aim of this prospective study was
to evaluate the impact of codon 158 COMT gene poly-
morphism on survival in a population-based cohort.
Results
The genotype distribution among the 2979 individuals
(1347 men and 1632 women) was in Hardy-Weinberg
equilibrium. The demographic data of the different geno-
type groups are shown in Table 2. The individuals in the
three genotype groups did not differ significantly with
regard to gender, age, body mass index, cholesterol level,
smoking status, level of physical activity, coffee intake,
prevalence of stroke, or education level. However, the
prevalence of ischemic heart diseases (including angina
pectoris and/or myocardial infarction) reported in con-
nection with the HUNT study in 1995–97 tended to be
lower among individuals with Val/Val genotype than
among those with other genotypes (6.4 percent vs. 8.6
percent, p = 0.09). The individuals with known genotype
were significantly older and had, accordingly, higher
mean systolic and diastolic BP and higher mean choles-
terol level than those without COMT data available (p <
0.05) (Table 2).
Overall mortality
212 (15.7 percent) men and 183 (11.2 percent) women
died during the follow up (p < 0.001). The distribution of
the COMT Val158Met alleles was similar among survivors
and the dead (Table 3), evident for both genders (data not
shown). No difference in survival was found for the differ-
ent genotypes (Fig. 1).
Death caused by neoplasms (ICD-10 C00-D48)
61 men (4.5 percent) and 44 women (2.7 percent) (p =
0.007) had neoplasm as the underlying cause of death. No
difference in cancer mortality was found between the dif-
Table 2: Clinical characteristics of the subjects according to COMT genotypes.
Characteristics No COMT genotyping (n = 62,247) Met/Met (n = 951) Met/Val (n = 1482) Val/Val (n = 546)
Sex, female (%) 53.2 54.0 55.1 55.1
Age, mean (SD) 49.1(18.9)$ 52.8 (18.3) 52.7 (18.2) 52.1 (18.0)
Education > 12 years (%) 19.0 17.4 15.7 16.7
Mean systolic blood pressure (mmHg)(SD) 137.6 (22.3)$ 140.9 (22.2) 140.4 (22.6) 141.6 (22.9)
Mean diastolic blood pressure (mmHg)(SD) 80.2 (12.5)$ 81.7 (12.4) 81.0 (12.6) 82.3 (12.9)
Body mass index, kg/m2 (SD) 26.4 (4.1) 26.3 (4.2) 26.4 (4.1) 26.3 (4.2)
Cholesterol, mmol (SD) 5.89(1.26)$ 6.02 (1.31) 6.03 (1.30) 6.08 (1.37)
Current smoking (%) 29.0 28.0 29.6 29.0
High level of physical activity* (%) 24.1 19.9 18.7 20.1
Coffee intake > 6 cups/day (%) 20.1 19.6 18.6 19.0
Use of antihypertensive medication (%) 11.0 12.6 13.3 11.2
Myocardial infarction (%) 3.3 3.7 3.5 2.8
Angina pectoris (%) 5.0 6.9 7.1 5.9
Stroke (%) 1.9 2.5 1.6 1.8
* High level of physical activity was defined as high intensity exercise more than 1 hour per week.
$ p < 0.05
Table 1: Primers and hybridization probes used for COMT 
Val158Met genotyping
Sequence
Primers: Forward 5'-ACGCCGTGATTCAGGAGCA-3'
Reverse 5'-GTCTTTCCTCAGCCCCAG-3'
Probes: Sensor 5'-TCACGCCAGCGAAATCCA-Fl*-3'
Anchor 5' LC Red 640#-ATCCGCTGGGTGATGGCG-3'
*Fl = Fluorescein
# LC Red 640 = Light Cycler Red 640
Underlined C indicates polymorphic siteBMC Medical Genetics 2007, 8:34 http://www.biomedcentral.com/1471-2350/8/34
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ferent Val158Met genotype groups (Table 4). Cancer in
the digestive system (C00-C26) was common among
women (39 percent), whereas 20 men (33 percent) died
because of prostate cancer (C61). Slightly more men with
Val/Val genotype had prostate cancer as underlying cause
of death than those with other genotypes (2.0 percent ver-
sus 1.4 percent, p = 0.44, long-rank test). However, no
such tendency was found when including 8 men with
prostate cancer as immediate or contributing cause of death
(2.0 percent versus 2.0 percent, p = 0.95, log-rank test)
Cardiovascular causes (ICD-10 I00-I00)
Cardiovascular disease was the underlying cause of death
in 97 men (7.2 percent) and 85 women (5.2 percent) (p =
0.02). Among these, 87 individuals died of ischemic heart
disease (I20-I25) and 34 of non-ischemic heart diseases
(I30-I33 or I39-I52) (Table 4). When the Met/Met and
Val/Met genotypes were pooled, a borderline significant
tendency to lower mortality caused by non-ischemic heart
diseases was found among individuals with Val/Val geno-
type (n = 2) compared to those with other genotypes (n =
32) (p = 0.06, rank-log test). Among the 62 individuals
with non-ischemic heart diseases as underlying (n = 34) or
immediate cause (n = 28) of death, subjects with Val/Val
had lower mortality rates (n = 4) than those with the Met/
Val or Met/Met genotypes (n = 58) (p = 0.015, rank-log
test) (Figure 2). The unadjusted relative risk of death by
non-ischemic heart diseases with Met/Met or Met/Val gen-
otypes was 3.27 (95% confidence interval, 1.19–9.00)
compared to Val/Val genotype. When we adjusted for age,
gender, smoking, coffee intake and body mass index the
relative risk decreased to 2.89 (95% confidence interval,
1.04–8.00).
Mortality among 69 with self-reported diabetes mellitus
During the 10 year follow up the overall mortality was
more than three times higher among the excluded 69 indi-
viduals with self-reported diabetes mellitus than among
the included sample of 2979 non-diabetic subjects
(47.8% versus 13.3%, p < 0.001). However, our results
were not substantially changed when we repeated the
analyses including these 69 diabetic persons. Specifically,
out of the 33 diabetic who died during the follow up, a
total of 6 had non-ischemic heart diseases as underlying (n
= 3) or immediate cause (n = 3) of death. Even when these
were included, subjects with Val/Val had lower mortality
rates (n = 6) than those with the Met/Val or Met/Met gen-
otypes (n = 62) (p = 0.04, rank-log test).
Discussion
In this population-based sample of individuals the
Val158Met polymorphism at the COMT  gene had no
impact on survival in general.
Survival curves for different genotypes Figure 1
Survival curves for different genotypes. Log-rank test: p = 
0.87.
11 10 9 8 7 6 5 4 3 2 1 0
Survival time (years)
1,00
0,96
0,92
0,88
0,84
0,80
C
u
m
 
S
u
r
v
i
v
a
l
Val/Val-censored
Val/met-censored
Met/Met-censored
Val/Val
Val/met
Met/Met
COMT
Table 3: Mortality from various causes by January 1, 2005 related to COMT genotypes and 5- and 10-year survival.
Met/Met (n = 951) Met/Val (n = 1482) Val/Val (n = 546) 5-year survival 10-year survival
n % n % n % p* p*
Genotypes
Total deaths 129 32.7 197 49.8 69 17.5 0.77 0.87
Neoplasms (C00-D48) 35 33.3 52 49.5 18 17.1 0.97 0.93
Cardiovascular causes (I00-I99) 58 31.9 92 50.5 32 17.6 0.47 0.96
All other causes 36 33.3 53 49.1 19 17.6 0.72 0.94
Alleles Met Val
Total deaths 455 57.6 335 42.4 0.35 0.63
Neoplasms (C00-D48) 122 58.1 88 41.9 0.74 0.48
Cardiovascular causes (I00-I99) 208 57.1 156 42.9 0.30 0.57
All other causes 125 57.9 91 42.1 0.98 0.51
* p value for the log-rank testBMC Medical Genetics 2007, 8:34 http://www.biomedcentral.com/1471-2350/8/34
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The strength of this study was the prospective cohort
design which provides a valuable complement to case-
control studies and with ability to adjust for potential
confounding factors [19]. Furthermore, the COMT geno-
typing was performed in a random sample of individuals
drawn from a genetically homogenous white Norwegian
population and being unselected except from the fact that
they did not have diabetes. Less than 3 percent of subjects
were of non-white ethnicity. Bias caused by admixed eth-
nicities may be reduced in population-based studies when
a genetically homogenous population is investigated.
The majority of included participants were selected com-
pletely at random, but were mixed together with a non-
diabetic group that were age-matched controls for the pur-
pose of a different genetic study on diabetes. It would
have been preferable to perform the analyses on a com-
pletely random selected population, including both dia-
betic and non-diabetic persons, but this strategy was not
possible because of the format of the data file. Because
diabetes status was a selection criterion for approximately
30 percent of the sample, we decided to exclude 69 indi-
viduals with diabetes mellitus, making the whole group
more homogenous. Individuals with Val/Val seem to be
less likely to be diabetic [16]. If true, because of a high
mortality rate among those with diabetes, the Val/Val gen-
otype should be associated with lower mortality rates. On
the other hand, one might speculatively assume that dia-
betic individuals with Val/Val genotype have a less favora-
ble prognosis and higher mortality than diabetics with
other genotypes. Thus, how the Val158Met polymor-
phism influences on mortality among persons with diabe-
tes mellitus is difficult to predict, but our exclusion of the
69 persons with self-reported diabetes probably minimize
the risk of bias. However, the main results were not sub-
Survival curves for different genotypes considering only  death from non-ischemic heart diseases (I30-I33, I39-I52) Figure 2
Survival curves for different genotypes considering only 
death from non-ischemic heart diseases (I30-I33, I39-I52). 
Log-rank test for Val/Val versus other genotypes: p = 0.015.
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Table 4: Causes of death according to COMT genotypes
Met/Met (n = 951) Met/Val (n = 1482) Val/Val (n = 546) Val/Val vs. other genotypes
n % n % n % Log-rank p value
Neoplasms (C00-D48) 35 3.7 52 3.5 18 3.3 0.74
Cancers in the digestive system (C00-C26) 14 1.5 14 0.9 4 0.7 0.39
Cancer in the respiratory system (C30-C39) 6 0.6 11 0.7 1 0.2 0.23
Breast cancer/cancer in female genital organs (C50-C58) 2 0.2 2 0.1 1 0.2 1.00
Prostate cancer (C61) 5 0.5 10 0.7 6 1.1 0.24
All other neoplasms 8 0.8 15 1.0 6 1.1 0.92
Cardiovascular causes (I00-I99) 58 6.1 92 6.2 32 5.9 0.77
Ischemic heart diseases (I20-I25) 29 3.0 43 2.9 15 2.7 0.78
Non-ischemic heart diseases (I30-I33 and I39-I52)# 12 1.3 20 1.3 2 0.4 0.06
Cerebrovascular diseases (I60-I69) 10 1.1 19 1.3 9 1.6 0.39
All other vascular deaths 7 0.7 10 0.7 6 1.1 0.33
Sudden death (R96) 1 0.1 3 0.2 1 0.2 0.92
Accidents (V01-V99, W00-W99, and X00-X99) 7 0.7 10 0.7 5 0.9 0.87
Dementia (F03, G30, and R54) 7 0.7 6 0.4 1 0.2 0.49
Diseases of the respiratory system (J00-J99) 12 1.3 13 0.9 5 0.9 0.95
Diseases of the digestive system (K00-K93) 3 0.3 7 0.5 4 0.7 0.33
Diseases of the kidney and ureter (N00-99) 3 0.3 5 0.3 0 0 0.31
Other diseases* 3 0.3 9 0.6 3 0.5 0.87
# Non-ischemic heart diseases (I30-I33 and I39-I52): Underlying cause of death among 34 individuals.
Additionally, immediate cause of death among 28 others (in total 62 individuals)
* Infections (A00-B99), diseases of the nervous system (G00-G99), mental and behavioral disorders (F00-F99), and other symptoms, sign, abnormal 
findings, ill-defined causes (R00-R94).BMC Medical Genetics 2007, 8:34 http://www.biomedcentral.com/1471-2350/8/34
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stantially changed when the analyses were repeated
including these 69 diabetic persons.
Our sample of 2979 individuals should have enough
power to detect a difference in survival between genotypes
that is of clinical interest, even when considering smaller
subgroups deceased because of neoplasms or heart dis-
eases. However, the number of individuals who died from
accidents, suicide, prostate cancer, non-Hodgkin lym-
phoma, breast cancer or cancer in female genital organs
was very low. For such relatively rare causes of death the
impact of Val158Met polymorphism needs to be evalu-
ated with other study designs. An example of this is a pro-
spective study from United Kingdom of 2430 women
with breast cancer reporting no effect on survival from
polymorphisms in the COMT gene [20].
In the present study no association between overall cardi-
ovascular mortality and Val158Met polymorphism was
found. However, when the Met/Met and Val/Met geno-
types were pooled, individuals with Val/Val genotype
tended to be less likely to die because of heart diseases
classified as I30-I33 or I39-I52 compared to those with
other genotypes, and the difference was significant even
when we controlled for the most important confounding
factors. It should be noted that this result may be due to
chance because of the multiple hypotheses being tested.
Hence, the association between the Val/Val genotype and
death from non-ischemic heart disease should be con-
firmed in a lager study.
Val/Val genotype is associated with high COMT enzyme
activity, and speculatively, rapid metabolism of circulat-
ing catecholamines may be protective for some type of
heart diseases e.g. the arrhythmias. Theoretically, haplo-
types of the COMT gene may influence COMT activity.
However, because of lack of financial and personnel
resources we did not evaluated other single nucleotide
polymorphisms within the COMT gene or in other genes,
and as a consequence, we did not have the opportunity to
evaluate haplotypes of the COMT gene or possible inter-
action with other genes.
Few other studies have evaluated the influence of COMT
genotypes on heart diseases. In accordance with our study,
in a Finnish cohort of 773 men, Met/Met genotype and
heavy coffee intake was associated with higher incidence
of acute coronary events than those with other genotypes
[16]. In contrast to our findings, a Swedish study found
the Met/Met genotype to be associated with decreased risk
of myocardial infarction, but this study was performed in
a highly selected group of hypertensive individuals [12].
Conclusion
In this population-based study evaluating the impact of
the COMT Val158Met polymorphism on survival among
2,979 adults, the polymorphism had no influence on
total mortality.
Methods
Study population
Between August 1995 and June 1997, all inhabitants aged
20 years or older in Nord-Trøndelag county in Norway (n
= 92,936) were invited to participate in the Nord-Trønde-
lag Health Survey ("Helseundersøkelsen i Nord-Trønde-
lag" = HUNT). In brief, two questionnaires including
more than 200 health-related questions were adminis-
trated to the participants. The population in Nord-Trøn-
delag County was ethnically homogeneous (less than 3
percent of subjects were of non-white ethnicity), making
it suitable for epidemiological genetic research [14].
Out of the 92,936 invited individuals, a total of 65,291
subjects (70 percent) answered the first questionnaire and
participated in the health examination. Details of the
non-participants are described elsewhere [14,15].
In the HUNT 2 biobank a total of 60,241 DNA samples
were available. Genotyping of the COMT locus was per-
formed among 3048 individuals. Approximately 70 per-
cent were selected completely at random, whereas the
remaining 30 percent included had been randomly
selected among an older group of individuals who did not
have self-reported diabetes mellitus. This latter group was
generated in connection with a planned genetic study on
diabetes that needed age-matched controls to a diabetic
population. In the present sample the prevalence of self-
reported diabetes mellitus was slightly lower among indi-
viduals with Val/Val genotype than the other genotypes
(2.0% versus 2.3%, p = 0.61), and also in a Finnish study
individuals with Val/Val were less likely to be diabetic
[16]. In the unidentified data file all participants were
mixed, and separate analyses of the group selected com-
pletely by random was not possible. Thus, with intention
to have a homogeneous study cohort, those with self-
reported diabetes (n = 69) in the randomly selected group
were eliminated [13], resulting in a population of 2979
individuals for the final analysis. All age groups were
included, but because the age-matched controls to a dia-
betic population as a group are older than the general
population, the total group of 2979 individuals without
self-reported diabetes was 3.5 years older (mean 52.6
years versus 49.1 years) than the HUNT population as a
whole.
Causes of death
We performed mortality follow-up by record linkage
using the Norwegian 11-digit birth number (date of birthBMC Medical Genetics 2007, 8:34 http://www.biomedcentral.com/1471-2350/8/34
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plus a 5-digit identifier), which is unique to each person
residing in Norway, to obtain the date and underlying
cause of death kept by Statistics Norway. The HUNT data
including genotyping at the COMT locus were linked to
the National Cause of Death register, and our report is
based on mortality follow-up through the year 2004. We
classified the 395 deaths on the basis of the underlying
cause of death coded at Statistics Norway by using the 9th
(death before 1996), or 10th revisions of the International
Classification of Diseases (ICD). To further explore the
influence of the Val158Met polymorphism on mortality
from cancer and heart diseases on death, we also evalu-
ated the immediate cause of death and up to five contribut-
ing causes of death. The underlying  cause of death was
defined as: a) the disease or injury that initiated the chain
of morbid events leading directly to death or b) the exter-
nal circumstances of the accident or violence that was the
cause of the fatal injury [17]. By immediate cause of death
was meant the disease, injury or condition directly leading
to death and which was caused by the underlying cause of
death [17]. Contributing cause of death was meant the con-
dition that may have contributed to the death, but was not
the direct causal relation with the disease or condition
that has caused the death [17].
Genotyping of the COMT locus
Blood sampling was done whenever subjects attended,
and details for the procedure and the HUNT 2 biobank are
described elsewhere [14]. DNA for genotyping was
extracted from peripheral blood leukocytes from whole
blood or blood clots stored in the HUNT 2 biobank, using
the Puregene kit (Gentra Systems Inc.) manually or with
an Autopure LS (Gentra Systems Inc.). Laboratory techni-
cians were blinded to the data from the National Cause of
Death register. COMT genotypes were determined using
the LightCycler (Roche Diagnostics Scandinavia AB, Bro-
mma, Sweden) fluorescence resonance energy transfer
method [18]. Polymerase chain reaction (PCR) amplifica-
tions were performed in 20 µl reactions on a LightCycler
System, using 2 µl genomic DNA and the LightCycler-
FastStart DNA Master Hybridization Probes kit (Roche
Diagnostics Scandinavia AB, Bromma, Sweden). PCR
primers (Eurogentec, Seraing, Belgium) and fluorescence
labeled probes (PROLIGO, Paris, France) are shown in
Table 1. Based on melting curve profiles, participants were
classified as having Val/Val, Val/Met, or Met/Met geno-
types. Details on PCR and melting curve conditions are
available on request.
Ethics
The study was approved by the Regional Committee for
Ethics in Medical Research, by the Norwegian Data
Inspectorate, and by the Directorate for Health and Social
Affairs.
Statistical analysis
Differences between continuous variables were tested
with analyses of variance (one-way ANOVA) and between
dichotomous variables with the chi-square test (including
Fisher's exact test). Analyses used two-tailed estimation of
significance, and p < 0.05 was considered to be statisti-
cally significant. A Kaplan-Meier method was performed
to estimate the cumulative survival and differences
between genotypes were tested with a log rank test. We
used the Cox proportional hazards model to adjust for
age, gender and other potential confounding factors,
including smoking status, level of education, use of alco-
hol, blood pressure, coffee intake and body mass index.
Overall, our sample of 2979 individuals had more than
80 percent power to detect a 3 percent difference in total
mortality and mortality by cancer or heart diseases
between pooled genotypes with 95 percent certainty.
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS), version 14.0 (SPSS
Inc, Chicago).
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